Grid Therapeutics LLC

Grid Therapeutics LLC develops innovative cancer therapies utilizing the human immune system to create novel tumor-specific therapeutic antibodies aimed at enhancing anti-tumor immunity. Grid Therapeutics LLC, founded in 2014, is based in Durham, US and specializes in oncology treatments. The company has raised a total of USD 4. 5 mn through a SERIES B funding round in March 2018, led by Milestone Holdings.

Edward Patz serves as the CEO and Founder, bringing significant expertise in oncology from previous ventures. Grid Therapeutics specializes in innovative cancer therapies by leveraging the human immune system to develop novel tumor-specific therapeutic antibodies. Their primary product, GT103, targets advanced stage non-small cell lung cancer (NSCLC) and is developed using single human B cells, enabling rapid generation of antibodies tailored to specific tumor antigens. The company's services cater primarily to healthcare providers and research institutions engaged in oncology, focusing on the North American market with potential expansion into international markets as their product pipeline matures.

Grid Therapeutics operates within a collaborative framework that includes partnerships with pharmaceutical companies and research organizations to enhance its clinical trials and product development. Revenue generation derives from licensing agreements, research collaborations, and milestone payments associated with their product candidates, particularly GT103. This business model emphasizes strategic partnerships that facilitate market access and distribution of their therapeutic solutions, allowing for future commercialization agreements with healthcare providers or research institutions involved in cancer treatment and research. Grid Therapeutics aims to expand its product offerings and enter new markets.

Following the SERIES B funding round in March 2018, which raised USD 4. 5 mn, the company plans to invest in further developing GT103 and exploring additional therapeutic candidates. Future geographic expansion may include targeting markets in Europe and Asia by 2022, contingent upon regulatory approvals and clinical trial progress. The recent funding will support these initiatives, particularly in advancing their clinical trials and enhancing collaboration with healthcare partners.